Trial Profile
Multicenter, double-blind, randomized, placebo-controlled study to evaluate the oral low-dose estradiol preparations SH T 04170 E (100 microg estradiol) and SH T 04170 F (190 microg estradiol) in postmenopausal women for the prevention of osteoporosis over two years
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs Estradiol (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Bayer HealthCare Pharmaceuticals
- 31 Mar 2022 Status changed from recruiting to completed.
- 10 Jun 2011 New trial record